Role of Antiarrhythmic Drugs: Frequent Implantable Cardioverter-Defibrillator Shocks, Risk of Proarrhythmia, and New Drug Therapy
- 1 April 2011
- journal article
- review article
- Published by Elsevier BV in Heart Failure Clinics
- Vol. 7 (2), 195-205
- https://doi.org/10.1016/j.hfc.2010.12.003
Abstract
No abstract availableThis publication has 54 references indexed in Scilit:
- Should Catheter Ablation be the Preferred Therapy for Reducing ICD Shocks?Circulation: Arrhythmia and Electrophysiology, 2009
- ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm AbnormalitiesCirculation, 2008
- Cardiac Device Implantation in the United States from 1997 through 2004: A Population-based AnalysisJournal of General Internal Medicine, 2007
- Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT EraJournal of Cardiovascular Pharmacology and Therapeutics, 2005
- Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillatorHeart Rhythm, 2004
- Implantable Cardioverter–DefibrillatorsNew England Journal of Medicine, 2003
- Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000The American Journal of Cardiology, 2003
- Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillatorsAmerican Heart Journal, 2000
- Adverse Events With Transvenous Implantable Cardioverter-DefibrillatorsCirculation, 1998
- Termination of Malignant Ventricular Arrhythmias with an Implanted Automatic Defibrillator in Human BeingsNew England Journal of Medicine, 1980